AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00841711 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Intensive Case Management
Description: Transitions involves the integration of evidence-based interventions, intensive case management that incorporates outreach elements similar to assertive community treatment (ACT). Intensive case management goes beyond the tenets of case management and incorporates community outreach. This model of case management has its roots in assertive community treatment (ACT) and has demonstrated a 37% greater reduction in homelessness and a 26% greater improvement in psychiatric symptom severity compared with standard case management treatments. As such, intensive case management is likely to result in important outcomes for the target population, is evidence-based and has been validated in prison-release programs.
Study NCT01128322 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-Amlodipine, Telmisartan
Study NCT03815994 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuromuscular Electrical Stimulation
Description: This device produces a muscle contraction in response to a externally generated low-voltage electric impulse, which is conducted through electrodes placed on the skin over the muscle group to be stimulated.
Study NCT03815994 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Neuromuscular Electrical Stimulation
Description: This device produces a muscle contraction in response to a externally generated low-voltage electric impulse, which is conducted through electrodes placed on the skin over the muscle group to be stimulated.
Study NCT04596332 — intervention group
Intervention type: OTHER
Intervention: no intervention measures
Description: Because this study was a retrospective study, no intervention measures were implemented for the patients enrolled.
Study NCT01992614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06678552 or Placebo
Description: PF-06678552 or placebo will be administered as an extemporaneously prepared solution once in each period.
Study NCT01128322 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: S-Amlodipine
Study NCT01128322 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telmisartan
Study NCT01128322 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01211509 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast
Description: After diagnosis of fBOS every day an oral capsule with 10 mg montelukast of placebo
Study NCT01211509 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Montelukast
Description: After diagnosis of fBOS every day an oral capsule with 10 mg montelukast of placebo
Study NCT04304170 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: VES002
Description: The sachets were to be dissolved in 200 ml of water at room temperature to be taken before breakfast.
Study NCT04304170 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The sachets were to be dissolved in 200 ml of water at room temperature to be taken before breakfast.
Study NCT00712621 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Counseling
Description: • Arm II: Patients receive audio visual aids and weekly counseling sessions by the expert counselors and breast cancer survivors over 8 weeks for a total of 8-16 sessions. Patients receive written materials from the counseling group after the completion of the sessions
Study NCT00712621 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Written materials
Description: • Arm I: Patients receive the support by providing existing resources. Patients receive standard written materials from the counseling group after enrolling in the study.
Study NCT04206475 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: rehabilitation
Description: the rehabilitation program consisted of an intensive treatment lasting 4 weeks, and including 3 daily interventions each working day (5 working days per week, for a total of 20 days of treatment and 60 sessions). The 3 daily sessions were organized as follows:~1 physio-kinesis and/or occupational therapy, 1 speech therapy, and 1 neuro-psychology treatment.~Each session lasted 45 minutes.
Study NCT04206475 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: rehabilitation
Description: the rehabilitation program consisted of an intensive treatment lasting 4 weeks, and including 3 daily interventions each working day (5 working days per week, for a total of 20 days of treatment and 60 sessions). The 3 daily sessions were organized as follows:~1 physio-kinesis and/or occupational therapy, 1 speech therapy, and 1 neuro-psychology treatment.~Each session lasted 45 minutes.
Study NCT04206475 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intensive Memory-Focused Training Program (IM-FTP)
Description: During each session, the patient was engaged in a one-to-one interaction with the therapist. Overall, the treatment targeted the following memory subfunctions: verbal and visuo-spatial short-term memory, verbal and visuo-spatial long-term memory, working memory and procedural memory
Study NCT02743780 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MGV354 ophthalmic suspension
Study NCT02743780 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MGV354 placebo
Description: Inactive ingredients used as placebo comparator
Study NCT04288258 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telehealth-Based Health and Wellness Program (POWERS-TBI)
Description: The treatment program is interactive and will be delivered via the internet, along with ongoing telephone health coaching calls designed to motivate, problem-solve challenges, reinforce skills learned, and prevent relapse.
Study NCT02696499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PA101B
Description: 40 mg PA101B administered via inhalation twice daily for 7 weeks
Study NCT02696499 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo administered via inhalation twice daily for 7 weeks
Study NCT00976378 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NOX-A12
Description: single ascending IV doses, ranging from 0.05 mg/kg to 10.8 mg/kg
Study NCT00316797 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 123-I INER
Description: Serial whole body planar imaging in the anterior and posterior projection will be performed at 1 min, 30 min, 1 h, 2h, 3h, 4h, 5h, 6h, 7h, 8h, and 18-24h following injection of 5 mCi of 123-I INER. Venous blood data will be acquired at each imaging time point. In addition a 24 hour urine collection will commence following radiotracer injection and urine sampled in five collections every 4 hours collection for first sixteen hours (4 collections), then one collection from 16 to 24 h. Whole body and source organs uptake will be analyzed on anterior and posterior images for calculating the radiation absorbed doses to organs using the MIRD method as described previously (Seibyl, et al, 1993). Plasma and urine metabolites will be characterized and safety assessments obtained.
Study NCT01602302 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bDMARD withdrawal (etanercept, adalimumab, infliximab, certolizumab, golimumab, tozilizumab, abatacept)
Description: bDMARDS (etanercept, adalimumab, infliximab, certolizumab, golimumab, tocilizumab, abatacept) will be discontinued after baseline visit in all participants
Study NCT02282215 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CLT-008
Description: Single intravenous infusion
Study NCT02282215 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: Daily subcutaneous injections
Study NCT02282215 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: G-CSF
Description: Daily subcutaneous injections
Study NCT04034966 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Claria telemedicine device
Description: Use of Claria telemedicine module, which stores patient information in the cloud.
Study NCT01898299 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial Direct Current Stimulation (tDCS)
Description: A neurostimulation technique that passes an extremely weak electric current through the brain.
Study NCT01898299 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: Sham (inactive) tDCS treatment
Study NCT04337593 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Basiliximab
Description: 20mg d1,8, repeated every 3 weeks
Study NCT04337593 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegaspargase
Description: 2500IU/㎡, d1,repeated every 3 weeks
Study NCT02496559 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pre-consultation CRP
Description: Use of CRP test on all children with fever before the consultation (intervention) compared to where the doctor requests a CRP test (no intervention)
Study NCT01170936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: canakinumab
Description: Single dose of canakinumab 300mg s.c. injection
Study NCT00917878 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Milk
Description: 500 mL low-fat milk added to high-fat meal
Study NCT00917878 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein
Description: Milk protein in 500 mL water added to high-fat meal
Study NCT00917878 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium
Description: Milk calcium in 500 mL water added to high-fat meal
Study NCT03477266 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mosapride
Description: Intake mouthly dissolving mosapride tablets in immediate post cesarean section
Study NCT03477266 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Dummy identical tablets to mouthly dissolving mosapride tablets
Study NCT01038934 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: samples collected by buccal cytobrush
Study NCT00976378 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NOX-A12
Description: single IV dose, at efficacious dose level
Study NCT00917878 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Control
Description: Lactose in 500 mL water added to high-fat meal
Study NCT04707027 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept Injection (2 mg/0.05 ml)
Description: Intravitreal aflibercept injections (treat and extend regimen)
Study NCT04707027 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Defer treatment
Description: Follow up with fundus photo and OCT every 4 weeks
Study NCT02485431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deflazacort
Study NCT03386747 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home visits to improve parenting behaviors
Description: Caregivers will be visited twice per month starting from the third trimester in pregnancy up to age three to discuss important health and development behaviors.
Study NCT03386747 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Center based parenting groups
Description: Caregivers will be invited to early childhood development groups. Groups will meet at nearby centers twice per month. Caregivers will be invited to participate starting from the third trimester up to age 3 of the child.
Study NCT04091984 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Prospera
Description: No Interventions, this is an observational study.
Study NCT04200768 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Prospective data and sample collection
Description: Performance of measurements of adiposity, extra collection of blood samples
Study NCT04218357 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probenecid
Description: safety
Study NCT04218357 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo
Description: Placebo
Study NCT03564405 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: UNI-DEB
Description: Applicate the TACE with UNI-DEB to unresectable hepatocellular carcinoma patient
Study NCT00074373 — intervention group
Intervention type: OTHER
Intervention: No intervention; observational
Study NCT01352741 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tapentadol Prolonged Release
Description: 100 - 500 mg per day orally twice daily for a maximum of 12 weeks
Study NCT01352741 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tapentadol Prolonged Release with Pregabalin
Description: Tapentadol Prolonged Release 100 - 300 mg per day with Pregabalin 150 - 300 mg per day orally twice daily for a maximum of 12 weeks
Study NCT01352741 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tapentadol Prolonged Release open label maintenance
Description: 100 - 400 mg per day Tapentadol Prolonged Release orally administered twice daily
Study NCT01352741 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tapentadol Prolonged Release open label maintenance
Description: 100 - 400 mg per day Tapentadol Prolonged Release orally administered twice daily
Study NCT04006990 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Provision of recliner chairs and encouragement to get out of bed
Description: Provision of recliner chairs and encouragement to get out of bed
Study NCT03589365 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Magnetic resonance imaging (MRI)
Description: Compare the left ventricular mass of a young adult population born prematurely (Prema group) to that of a group of young adults born at term (Witness group~The measurements made during this examination are:~Coronary Reserve Presence of fat in the myocardium Left ventricular mass Left ventricular volume~The measurements made during this examination are:~Coronary Reserve Presence of fat in the myocardium Left ventricular mass Left ventricular volume
Study NCT02282371 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Study NCT02282371 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BYL719
Study NCT02282371 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMRT (Intensity-Modulated Radiation Therapy)
Study NCT02463032 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GTx-024
Description: To determine whether either or both doses result in an acceptable clinical benefit rate.
Study NCT01257490 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: counseling vs. advice
Description: 1 session of brief physician advice to quit smoking plus bupropion (12 weeks) compared to 4 sessions of intensive counseling plus bupropion (12 weeks)
Study NCT01257490 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: counseling vs. advice
Description: 1 session of brief physician advice to quit smoking plus bupropion (12 weeks) compared to 4 sessions of intensive counseling plus bupropion (12 weeks)
Study NCT04503590 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Minimally Invasive Micro Sclerostomy (MIMS)
Description: The System is a surgical device, designed to create a drainage channel at the sclera-corneal junction . The drainage channel is created by a Stainless Steel surgical tool.
Study NCT02448953 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Two-field lymphadenectomy
Description: Thoracic-upper abdominal two-field lymphadenectomy
Study NCT02448953 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Three-field lymphadenectomy
Description: Cervical-thoracic-upper abdominal three-field completely lymphadenectomy
Study NCT00574665 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hyperinsulinemic Hyperglycemic Clamp
Description: Glucose Clamp
Study NCT00060814 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combined intervention
Description: 300 mg bupropion plus 4mg nicotine gum ad lib plus motivational interviewing counseling
Study NCT04070196 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Periplex
Description: Periplex test strip will be used to examine the PD effluent for peritonitis, in addition to the routine leucocyte testing of PD effluent
Study NCT03918226 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: exploratory laparotomy
Description: Patients presenting with acute abdomen were operated. Exploratory Laparotomy of patients was done. Further procedure was done according to peroperative findings. Ileostomy for perforation of gut, stricturoplasty for strictutre, biopsy for mesentric lymphadenopathy
Study NCT00383734 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Newfill
Description: 1 to 7 injections of drug
Study NCT00383734 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Eutrophill
Description: 1 to 7 injections of drug
Study NCT04363593 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Serological test
Description: Serological testing is performed for patients with confirmed COVID-19 infection by RT-PCR.
Study NCT04363593 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Serum test
Description: Use of the serum taken from patients consulted for suspicion of COVID-19 before the beginning of the trial
Study NCT03553498 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV acetaminophen
Description: acetaminophen given intravenously
Study NCT03553498 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: IV placebo
Description: given intravenously
Study NCT03553498 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydromorphone
Description: hydromorphone given intravenously
Study NCT02677766 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: occupational therapy
Description: an intervention phase in the period of hospitalization for rehabilitation in the hospital, aimed mainly at achieving objectives related to the area of self-care and, secondly, the objectives in the areas of productivity and leisure, identified at T0; plus an intervention in the post-discharge at the patient's home, aimed primarily at achieving objectives related to the areas of productivity and leisure time and, secondly, to possible targets in residues of self-care, identified in T0.
Study NCT02677766 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Usual care consists in rehabilitation treatment delivered by a multidisciplinary team
Study NCT04131556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maribavir
Description: Participants in both part 1 and part 2 of the study will receive maribavir tablet or suspension orally depending upon the treatment sequence allocation for a total of 7 and 10 days respectively.
Study NCT00664599 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Infusion of Rituximab, 1500 mg, two times with 15 days interval. Patients receive also Methotrexate (15 mg weekly) and Prednisolone (0.5 mg/daily).
Study NCT03553498 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: hydromorphone
Description: hydromorphone given intravenously
Study NCT02156817 — intervention group
Intervention type: OTHER
Intervention: Amplitude integrated electroencephalogram, Cardiorespiratory signal acquisition
Study NCT00047619 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulsatile Lavage
Description: pulsatile lavage to wound bed
Study NCT00047619 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham pulsatile lavage
Description: pulsatile lavage to not directed at wound or patient
Study NCT01922063 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physiotherapy Intervention
Description: 20x 30 min sessions of physiotherapy
Study NCT01922063 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham neck massage
Description: 20x 30 minutes sessions of neck massage
Study NCT01912157 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Expressive Writing
Description: The intervention consists in 3 self-applied solitary written disclosure sessions (expressive writing)
Study NCT01912157 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Expressive Writing
Description: The intervention consists in 3 self-applied solitary written disclosure sessions (expressive writing)
Study NCT00846040 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reduced fat diet
Description: RF (selective reduction of 85% of baseline fat calories per day)
Study NCT00846040 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reduced carbohydrate diet
Description: RC (selective reduction of 60% of baseline carbohydrate calories per day)
Study NCT00846040 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Drug: f-18 fallypride
Description: Dopamine D2 receptor availability is measured by positron emission tomography (PET) using the positron emitting compound \[18F\] fallypride which binds competitively with dopamine to the D2 receptor.
Study NCT00846040 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: f-18 fallypride
Description: Dopamine D2 receptor availability is measured by positron emission tomography (PET) using the positron emitting compound \[18F\] fallypride which binds competitively with dopamine to the D2 receptor.
Study NCT03433391 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Oxiplex
Description: Oxiplex is a clear, viscoelastic gel that is applied to operative site during lumbar spine surgery in order to coat the nerve root with a protective barrier.
Study NCT00846040 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: fMRI
Description: Functional MRI (fMRI) will be used to measure the effects of diet and weight loss on regional brain activity